Effect of TCNU on Lung Cancer in Mice
Author Information
Author(s): R.J. Fergusson, L.E. Anderson, J.S. Macpherson, P. Robins, J.F. Smyth
Primary Institution: Imperial Cancer Research Fund
Hypothesis
Does the new nitrosourea TCNU show activity against human lung cancer xenografts in immunodeficient mice?
Conclusion
TCNU demonstrated moderate activity against non-small cell lung cancer and was curative in small cell lung cancer xenografts.
Supporting Evidence
- TCNU caused a delay in the growth of all three xenografts.
- Moderate activity was observed in two non-small cell tumors.
- TCNU was curative in the small cell xenograft NX004.
Takeaway
Researchers tested a new cancer drug called TCNU on mice with lung cancer, and it helped some of the tumors shrink or disappear.
Methodology
The study involved administering TCNU to human lung cancer xenografts in immunodeficient mice and measuring tumor growth delays.
Limitations
The study was conducted in mice, and the results may not directly translate to humans.
Participant Demographics
The study used immunodeficient male CBA/Lac mice.
Want to read the original?
Access the complete publication on the publisher's website